LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

Search

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

9.1 -2.67

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.82

Максимум

9.49

Ключови измерители

By Trading Economics

Приходи

-2M

-13M

Служители

42

EBITDA

-2.1M

-13M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+348.24% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-88M

881M

Предишно отваряне

11.77

Предишно затваряне

9.1

Настроения в новините

By Acuity

37%

63%

116 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.09.2025 г., 22:41 ч. UTC

Значими двигатели на пазара

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12.09.2025 г., 16:04 ч. UTC

Значими двигатели на пазара

Upexi Shares Climb on Solana Gains

14.09.2025 г., 23:48 ч. UTC

Пазарно говорене

Oil Futures Mixed Amid Divergent Signals -- Market Talk

14.09.2025 г., 23:41 ч. UTC

Пазарно говорене

Gold Edges Lower on Likely Technical Correction -- Market Talk

14.09.2025 г., 23:38 ч. UTC

Пазарно говорене

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

14.09.2025 г., 23:13 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

14.09.2025 г., 23:13 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

14.09.2025 г., 23:13 ч. UTC

Пазарно говорене

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

14.09.2025 г., 23:13 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.09.2025 г., 23:04 ч. UTC

Пазарно говорене

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

13.09.2025 г., 08:20 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

12.09.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

12.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.09.2025 г., 20:09 ч. UTC

Печалби

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12.09.2025 г., 19:23 ч. UTC

Пазарно говорене

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12.09.2025 г., 19:16 ч. UTC

Пазарно говорене

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12.09.2025 г., 19:03 ч. UTC

Пазарно говорене

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12.09.2025 г., 18:59 ч. UTC

Пазарно говорене

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12.09.2025 г., 18:38 ч. UTC

Пазарно говорене
Печалби

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12.09.2025 г., 18:33 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12.09.2025 г., 18:22 ч. UTC

Пазарно говорене

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12.09.2025 г., 16:56 ч. UTC

Пазарно говорене

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12.09.2025 г., 16:22 ч. UTC

Печалби

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12.09.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.09.2025 г., 16:19 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12.09.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

12.09.2025 г., 16:11 ч. UTC

Печалби

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12.09.2025 г., 15:37 ч. UTC

Пазарно говорене

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12.09.2025 г., 15:22 ч. UTC

Пазарно говорене

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12.09.2025 г., 15:07 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

348.24% нагоре

12-месечна прогноза

Среден 42 USD  348.24%

Висок 42 USD

Нисък 42 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

1

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

116 / 371 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
help-icon Live chat